A Comparison Of Diagnostic Accuracy Of Cystatin C With Creatinine In The Sample Of Patient Of T2 DM With Diabetic Nephropathy

Similar documents
Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation

International Journal of Pharma and Bio Sciences IS CYSTATIN C ESTIMATION A BETTER MARKER IN CHRONIC KIDNEY DISEASE PATIENTS?

Glomerular Filtration Rate. Hui Li, PhD, FCACB, DABCC

Comparison of Estimated Glomerular Filtration Rate Using Different Analytes in Chronic Kidney Disease Patients

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Comparison of Serum Cystatin C and Creatinine Levels to Evaluate Early Renal Function after Kidney Transplantation

Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1

Introduction to Clinical Diagnosis Nephrology

Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy.

Cystatin C (serum, plasma, urine)

Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction

5/10/2014. Observation, control of blood pressure. Observation, control of blood pressure and risk factors.

BCH472 [Practical] 1

Cystatin C: A New Approach to Improve Medication Dosing

AGING KIDNEY IN HIV DISEASE

ISSN X (Print) Research Article. *Corresponding author GadAllah Modawe

Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης

Acute renal failure Definition and detection

Case Studies: Renal and Urologic Impairments Workshop

Professor and Director. Children s Hospital of Richmond

RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.

Validity of the use of Schwartz formula against creatinine clearance in the assessment of renal functions in children

Serum and urinary markers of early impairment of GFR in chronic kidney disease patients: diagnostic accuracy of urinary -trace protein

Non-protein nitrogenous substances (NPN)

THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS

Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

Clinical Usefulness of Serum Cystatin C as a Marker of Renal Function

BASELINE CHARACTERISTICS OF THE STUDY POPULATION

Renal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.

Characteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests

Creatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC

A Study on Estimated Glomerular Filtration Rate As A Predictor of Renal Dysfunction Among Adult Hiv Patients on Highly Active Antiretroviral Therapy

Introduction to the kidney: regulation of sodium & glucose. Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health

Diabetes and Hypertension

Early Identification of the Diabetic Nephropathy; Beyond Creatinine

Morbidity & Mortality from Chronic Kidney Disease

Comparison of Modified Jaffe s Kinetic Method and Enzymatic Method of Serum Creatinine Estimation for Precision, Linearity and Effect of Interferent

BIOL 2402 Renal Function

Assessing Renal Function: What you Didn t Know You Didn t Know

Renal Protection Staying on Target

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Renal Clearance. Dr. Eman El Eter

QUICK REFERENCE FOR HEALTHCARE PROVIDERS

INTERNATIONAL JOURNAL OF ANATOMY PHYSIOLOGY AND BIOCHEMISTRY

מסקנות מיישום סטנדרטיזציה של בדיקת קראטינין : שימוש בנוסחאות לחישוב egfr

AKI: definitions, detection & pitfalls. Jon Murray

Hepatitis B Vaccination in Chronic Kidney Disease:- Experience in A Tertiary Care Centre

JMSCR Vol 07 Issue 01 Page January 2019

Nephron Function and Urine Formation. Ms. Kula December 1, 2014 Biology 30S

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Study of Micro Albuminuria and Other Parameters in NIDDM Individuals

RENAL FUNCTION ASSESSMENT ASSESSMENT OF GLOMERULAR FUNCTION ASSESSMENT OF TUBULAR FUNCTION

A New Approach for Evaluating Renal Function and Its Practical Application

(KFTs) IACLD CME, Monday, February 20, Mohammad Reza Bakhtiari, DCLS, PhD

Renal Function and Associated Laboratory Tests

How and why to measure renal function in patients with liver disease?

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Chapter 23. Composition and Properties of Urine

JMSCR Vol 06 Issue 12 Page December 2018

DIABETES MEASURES GROUP OVERVIEW

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

Have you seen a patient like Elaine *?

Clinical Profile and Complications of UTI In Diabetic Patients

Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population

Comparison between a serum creatinineand a cystatin C-based glomerular filtration rate equation in patients receiving amphotericin B

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives

Thyroid Hormones and Lipid Profile Changes during Hemodialysis in CKD Cases of Libya

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Management of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA

Supplementary Appendix

SPRINT: Consequences for CKD patients

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

Discovery & Validation of Kidney Injury Biomarkers

Uric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George

Understanding. Your Kidneys. Laurie Biel, RN,BSN, CNN The MGH Center For Renal Education March 28, 2016

Correlation of hyperuricemia with microalbuminuria in patients with type 2 diabetes mellitus in relation to glycemic control.

International Journal of Pharma and Bio Sciences SERUM CYSTATIN C AND MICROALBUMIN IN THE DETECTION OF EARLY NEPHROPATHY IN TYPE II DIABETIC PATIENTS.

Dr A Pokrajac MD MSc MRCP Consultant

CYSTATIN C. An Improved Way To Screen For Chronic Kidney Disease INNOVATIONS IN CLINICAL DIAGNOSTICS

Validation of El-Minia Equation for Estimation of Glomerular Filtration Rate in Different Stages of Chronic Kidney Disease

Improved Prediction of Decreased Creatinine Clearance by Serum Cystatin C: Use in Cancer Patients before and during Chemotherapy

Impact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients

Cystatin C and renal function in pediatric renal transplant recipients

SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection

Early Detection of Chronic Kidney Disease (CKD)

A STUDY ON DYSLIPIDAEMIA IN CHRONIC KIDNEY DISEASE (CKD) WITH SPECIAL REFERENCE TO HAEMODIALYSIS

Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care

Journal of Chemical and Pharmaceutical Research, 2015, 7(6): Research Article

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

Evaluation of Renal Damage by Urinary Beta-Trace Protein in Patients with Chronic Kidney Disease

The estimation of kidney function with different formulas in overall population

Update on HIV-Related Kidney Diseases. Agenda

SERUM AMYLASE IN PATIENTS WITH CHRONIC KIDNEY

Evaluation. Abstract: Introduction: Micro-vascular. ESRD. Due ARTICLE 1,2. treatment for DM Bhubaneswar life span resulting 3 Tutor.

Clearance and Reabsorption. Use the following data to answer these questions. a. plasma flow rate in the afferent arterioles:

Transcription:

IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 7 Ver. V (July. 2017), PP 53-57 www.iosrjournals.org A Comparison Of Diagnostic Accuracy Of Cystatin C With Creatinine In The Sample Of Patient Of T2 DM With Diabetic Nephropathy * Dr Rahul Singh 1, Dr. Aarti. B. Bhattacharya 2, Dr. S. P. Saxena 3 1 Resident Department of Pathology, Hind Institute of Medical Sciences, Barabanki, U.P 2 Professor Department of Biochemistry, Hind Institute of Medical Sciences, Barabanki, U.P 3 Assistant Professor Department of Medicine, Hind Institute of Medical Sciences, Barabanki, U.P Corresponding author: * Dr Rahul Singh Abstract: Objective: To compare the diagnostic accuracy of cystatin C with creatinine in the sample of patient of T2 DM with diabetic nephropathy. Methods: The target population of this study comprised the adult males and females who have T2DM for different period of time and aged between 30-60 years from outpatient diabetic clinics. Another group of apparently healthy individuals represented the control group.the sample size was 70 patients which were previously diagnosed as having T2DM as cases and 70 healthy individuals. Results:The cystatin was found to be significantly (p=0.0001) higher in cases (3.05±1.29) compared to controls (0.92±0.12). The creatinine was found to be significantly (p=0.0001) higher in cases (6.08±4.22) compared to controls (0.90±0.15).The sensitivity and specificity of cystatin ( 1.17) was 95.7% and 97.1% respectively. The sensitivity and specificity of creatinine ( 1.07) was 95.7% and 77.1%. Conclusion: The study found high sensitivity and specificity of cystatin C and creatinine for T2 DM with diabetic nephropathy. Keywords: Diagnostic accuracy, Diabetic nephropathy, Cystatin C, Creatinine I. Introduction Diabetes mellitus is a metabolic disease characterized by defects in insulin secretion, insulin action or both. The number of people with diabetes is increasing due to population growth, aging, urbanization and the increasing prevalence of obesity and physical inactivity. Approximately 40% of patients with type I diabetes and 5-15% of patients with type II diabetes eventually develop End Stage Renal Disease (ESRD) (Evans and Cappel, 2000). Even a diabetic patient is under treatment, there is a risk of development of nephropathy. The risk is related to the length of time the person has diabetes. There is good evidence that early treatment delays or prevents the onset of diabetic nephropathy. Therefore, prevention of diabetic renal disease or at least the postponement of or slowing down the disease process, has emerged as a key issue (Mussap et al, 2002). However, the ability to assess renal function is poor in early diabetic nephropathy, when active management is important (Tan et al, 2002). Glomerular filtration rate (GFR) is the best overall index of renal function in health and disease. Serum creatinine and creatinine clearance are the most widely used indices for the routine noninvasive estimation of GFR. Creatinine is usually measured by the Jaffe reaction, based on a complex formation between alkaline picrate and creatinine (Hojs et al, 2006).The serum creatinine concentration may be significantly influenced by several extra renal factors. Serum creatinine is considered relatively specific but not very sensitive because serum creatinine remains in the normal range until 50% of renal function is lost. The aim of this study was to compare the diagnostic accuracy of cystatin C with creatinine in the sample of patient of T2 DM with diabetic nephropathy. II. Material And Methods Study design This was a case-control study. Study site The study was conducted in the Department of Pathology, Hind Institute of Medical Sciences, Barabanki. Study subjects The target population of this study comprised the adult males and females who have T2DM for different period of time and aged between 30-60 years from outpatient diabetic clinics. Another group of apparently healthy individuals represented the control group. DOI: 10.9790/0853-1607055357 www.iosrjournals.org 53 Page

Sample size The sample size was 70 patients which were previously diagnosed as having T2DM as cases and 70 healthy individuals Exclusion criteria A. Cases Diabetics with urinary tract infections (UTI), Diabetics suffering from renal or liver disease, Diabetics who had high blood pressure: more than 130/80 mmhg, Females who were pregnant. Controls Subjects with fasting blood glucose 125mg/dl, Subjects with UTI, Subjects suffering from renal or liver disease, Subjects who had high blood pressure: more than 130/80 mmhg, Females who were be pregnant. Ethical considerations The ethical clearance was taken from the Ethical Committee of the institute Informed consent The written informed consent was taken from each patient before enrolling in the study. The subjects were explained about the objectives of the study. Data collection A meeting interview was used for filling the questionnaire from both cases and controls. All the interviews was conducted face to face by the researcher. Personal data will be collected. The questionnaire included issues about personal information like name, sex, age, weight, height, blood pressure, time of diagnosis (for patients only), smoking and family history of diabetes in first-degree relatives, (father, mother, sister and brother). In addition, it included other information like type of medication and complication of diabetes (retinopathy, CVD and neuropathy). Specimen collection Convenient sampling method was used for selection of the study population, in order that every individual had to meet the criteria of being included in the sample. For both members of the case and control group, blood and urine samples were collected under quality control and safety procedure. Blood sampling and processing Fasting overnight venous blood sample (about 5 ml) will be drawn from each control and diabetic individual. The blood was collected in plain vacutainer tubes and left for a while to allow blood to clot. Then clear serum sample was obtained by centrifugation at room temperature at 3500 rpm for 10 minutes and collected into two plastic tubes, then will be stored at -20 C for no more than one month until the time of analysis. Urine sampling and processing Urine sample from both patients and controls were collected in a plastic container. The urine samples were immediately centrifuged at 2000 rpm for 10 minutes. Routine urine test was performed to each sample in order to exclude cases that had UTI. 5 ml from each sample supernatant were distributed equally into two plastic tubes and then was stored at -20 C for no more than one month until the time of chemical assay. Biochemical analysis Serum cystatin C, glucose, urea, creatinine, cholesterol, triglycerides and urine albumin was analyzed using chemistry automated analyzer. Statistical analysis Data was analyzed using Statistical Packages for Social Science (SPSS 16.0 USA). The relationships between some qualitative categories was identified statistically by using Chi-square test. Independent t test was applied to compare means two cases and contros. The one-way analysis of variance (ANOVA) was used to determine whether there was any significant difference among the means. To assess the correlation between biochemical parameters, Pearson s correlation coefficient (r) was applied. ROC analysis was employed to calculate the AUC. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of cystatin and creatinine were calculated. All results will be considered significant if P < 0.05. III. Results About one third of cases (32.9%) and 10% of controls were between 41-50 years. However, 24.3% of cases and 45.7% of controls were between 31-40 years. There was no significant (p>0.05) difference in the age between the groups showing comparability of the groups in terms of age. Majority of the cases (68.6%) and controls (71.4%) were males. There was no significant (p>0.05) difference in the gender between the groups showing comparability of the groups in terms of gender (Table-1). The cystatin was found to be significantly (p=0.0001) higher in cases (3.05±1.29) compared to controls (0.92±0.12). The creatinine was found to be significantly (p=0.0001) higher in cases (6.08±4.22) compared to controls (0.90±0.15) (Table-2). The sensitivity and specificity of cystatin ( 1.17) was 95.7% and 97.1% respectively (Table-3 & Fig.1). The sensitivity and specificity of creatinine ( 1.07) was 95.7% and 77.1% respectively (Table-4 & Fig.2). DOI: 10.9790/0853-1607055357 www.iosrjournals.org 54 Page

IV. Discussion Gold standard methods of assessing GFR are replaced by an estimated GFR derived from endogenous substances. Serum creatinine is the most widely used substance to estimate GFR. Creatinine concentration is influenced by sex, age, diet and muscle mass. It only increases once GFR reduction of about 50% is present. This leads to falsely high or low values, limiting its usefulness as an ideal marker of GFR (Richard et al, 2011). Cystatin C is a low molecular weight protein produced at a constant rate by all nucleated cells. It is freely filtered by glomerulus, completely reabsorbed and catabolized in the proximal tubule. Serum cystatin C is reported to be modulated by several non-renal factors like steroids, thyroid status, smoking, C-reactive protein and malignancy. Despite these limitations evidence continues to suggest superiority of serum cystatin C when compared with serum Creatinine in patients with early and moderately decreased renal function (Christensson et al, 2004; Hojs et al, 2006). The study shows significant increase in serum cystatin C and creatinine levels in diabetic individuals compared to controls. In the present study, the cystatin was found to be significantly (p=0.0001) higher in cases (3.05±1.29) compared to controls (0.92±0.12). The creatinine was also found to be significantly (p=0.0001) higher in cases (6.08±4.22) compared to controls (0.90±0.15). These findings are similar to a study conducted by Borges et al (2010). The inability of creatinine to detect early decline in GFR is due to the fact that SCr levels only begin to rise above the normal range when approximately 50% of renal function is already lost, suggesting that GFR can change before SCr becomes abnormal (Shemesh et al, 1985). Evidences suggest that serum cystatin c may rise faster than creatinine after a fall in GFR and is a reliable endogenous marker for assessing renal function in type 2 diabetic patients with renal impairment. In one study, including 52 type 2 diabetic patients, an early and more significantly increased levels of serum cystatin C than SCr was observed as GFR decreases, which indicated that serum cystatin C might be a useful marker for detecting early renal impairment in diabetic patients (Hamed et al, 2011). In this study, the sensitivity and specificity of cystatin ( 1.17) was 95.7% and 97.1% respectively. The sensitivity and specificity of creatinine ( 1.07) was 95.7% and 77.1% respectively.zati et al (2013) analysed blood and urine samples from 418 normal subjects and 37 Type 2 diabetes patients (T2DM) with chronic kidney disease (CKD). The calculated sensitivity, specificity and accuracy of egfr-creatinine were 85%, 87.2% and 85% respectively. The egfr- cystatin C showed higher sensitivity, specificity and accuracy than egfrcreatinine in studied diabetic subjects. Zhang et al (2010) evaluated the usefulness of serum cystatin C (CysC) as a marker of renal function in 83 patients with diabetic nephropathy, considering multiple factors including tubular function and body mass index. Meta-analysis showed that the serum cystatin C had no heterogeneity (P=0.418, I2=2.2%, DOR=25.03), while creatinine heterogeneity was high (P=0.109, I2=37.5%, DOR=9.11). The values of SEN, SPE and SAUC were calculated as 0.86, 0.70 and 0.9015 for cystatin C and 0.78, 0.73 and 0.8285 for creatinine individually. This study utilized GFR detection and subgroups analysis by cutoff. V. Conclusion The study found high sensitivity and specificity of cystatin C and creatinine for T2 DM with diabetic nephropathy. References [1]. Evans TC, Cappel P. Diabetic Nephropathy. Clinical Diabetes 2000; 18:7-21. [2]. MussapM,DallaVestra M, Fioretto P, Saller A, Varagnolo M, et al. (2002)Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients.kidneyint 61: 1453-1461. [3]. Tan GD, Lewis AV, James TJ, AltmannP,Taylor RP, Levy JC.Clinical Usefulness of Cystatin C for the Estimation of Glomerular Filtration Rate in Type 1 Diabetes. Diabetes Care 2002; 25: 2004-9. [4]. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant. 2006;21:1855-62. [5]. Richard J. MacIsaac, EroshaPremaratne, George Jerums. Estimating glomerular filtration rate in diabetes using serum cystatin C. ClinBiochem Rev. 2011 May;32:61-7. [6]. Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, Sundkvist G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004;256:510-8. [7]. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, Batista MC. Is cystatin C a useful marker in the detection of diabetic kidney disease? Nephron ClinPract. 2010;114(2):127-34. [8]. Shemesh O, Golbetz H, Kriss JP, Myers BD (1985) Limitations of creatinine as a filtration marker in glomerulopathicpatients.kidneyint 28: 830-838. [9]. Hamed EO, Zaky NA, Kamal YM (2011) Simple cystatin-c formula for estimation of glomerular filtration rate in chronic kidney disease in diabetic patients. AAMJ 9:81 89. [10]. Zhang PP, Zhan JF, Xie HL, Li LS, Liu ZH (2010) Evaluation of glomerular filtration rate using cystatin C in diabetic patients analysed by multiple factors including tubular function.jint Med Res 38: 473-483. DOI: 10.9790/0853-1607055357 www.iosrjournals.org 55 Page

Table-1: Distribution of age between cases and controls Age in years Cases (n=70) Controls (n=70) p-value 1 No. % No. % 20-30 6 8.6 8 11.4 0.06 31-40 17 24.3 32 45.7 41-50 23 32.9 7 10.0 51-60 14 20.0 16 22.9 >60 10 14.3 7 10.0 Mean±SD 46.51±13.94 40.97±12.50 Male 48 68.6 50 71.4 0.71 Female 22 31.4 20 28.6 1 Chi-square test Table-2: Comparison of cystatin C between cases and controls Groups Cyststatin (mg/dl) (Mean±SD) Creatinine (mg/lt) (Mean±SD) Cases 3.05±1.29 6.08±4.22 Controls 0.92±0.12 0.90±0.15 p-value 1 0.0001* 0.0001* 1 Unpaired t-test, *Significant Table-3: Diagnostic value of Cystatin for DN Cystatin cut off ( 1.17) Cases Control Total 1.17 67 2 69 <1.17 3 68 71 Total 70 70 140 Sensitivity 95.7 Specificity 97.1 PPV 97.1 NPV 95.8 Accuracy 96.4 AUC (95%CI)=0.98 (0.95-0.99), p=0.0001 Fig. 1: ROC showing sensitivity and specificity of Cystatin for DN DOI: 10.9790/0853-1607055357 www.iosrjournals.org 56 Page

Table-4: Diagnostic value of creatinine for DN Creatinine cut off ( 1.07) Cases Control Total 1.07 67 16 83 <1.07 3 54 57 Total 70 70 140 Sensitivity 95.7 Specificity 77.1 PPV 80.7 NPV 94.7 Accuracy 86.4 AUC (95%CI)=0.97 (0.94-0.99), p=0.0001 Fig. 2: ROC showing sensitivity and specificity of creatinine for DN *Dr Rahul Singh. "A Comparison Of Diagnostic Accuracy Of Cystatin C With Creatinine In The Sample Of Patient Of T2 DM With Diabetic Nephropathy." IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) 16.7 (2017): 53-57. DOI: 10.9790/0853-1607055357 www.iosrjournals.org 57 Page